Mauna Kea Technologies Announces 7 Presentations Highlighting the Clinical Value of Cellvizio® in Gastrointestinal Diseases at Digestive Disease Week® (DDW) 2021 Virtual™

Further validation of how the use of Cellvizio potentially impacts patient management and improves outcomes in multiple gastrointestinal indications

Paris and Boston, May 20, 2021 – 05:45 PM CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the presentation of 7 abstracts supporting Cellvizio® at Digestive Disease Week® (DDW) 2021 Virtual™, being held May 21-23. These abstracts focus on Barrett’s esophagus (BE), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and associated food allergies, pancreatic cysts and other gastrointestinal diseases. Studies are focused on how the use of Cellvizio potentially impacts patient management and improves outcomes.

“Real-time in vivo cellular imaging with Cellvizio is once again taking center stage at Digestive Disease Week as evidenced by the many high-quality studies presented this year,” said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies. “We are excited to see the number and range of studies being presented and discussed, supporting how the use of Cellvizio potentially impacts patient management and improves outcomes in Barrett’s esophagus, pancreatic cysts, and inflammatory bowel disease applications, and highlighting the important new role Cellvizio could play in the management of patients suffering from irritable bowel syndrome, a chronic functional disorder of the gastrointestinal system affecting approximately 9.2% of the global population.”

Highlighted featured presentations (in chronological order):

CONFOCAL LASER ENDOMICROSCOPY IN THE COLONIC MUCOSA OF PATIENTS WITH DIVERTICULAR DISEASE: INTERIM RESULTS
Presentation #156
Friday, May 21 from 1:47 – 1:53 p.m. ET
Presenting Author: Miguel Puga-Tejada, Instituto Ecuatoriano de Enfermedades Digestiva, Ecuador

ACCURACY AND AGREEMENT OF AN INTERNATIONAL PANEL FOR THE DIAGNOSIS OF PANCREATIC CYSTIC LESIONS USING EUS-GUIDED NEEDLE-BASED CONFOCAL LASER ENDOMICROSCOPY
Presentation #78
Friday, May 21 from 2:02 – 2:16 p.m. ET
Presenting Author: Jorge Machicado, Mayo Clinic Health System, Eau Claire, Wisconsin, United States

CONFOCAL LASER ENDOMICROSCOPY IN COMBINATION WITH MOLECULAR BIOMARKERS FOR THE DIAGNOSIS OF INCONSPICUOUS DYSPLASIA IN BARRETT’S ESOPHAGUS: A RANDOMISED CROSS-OVER TRIAL
Presentation #227
Friday, May 21 from 1:47 – 1:53 p.m. ET
Presenting Author: Mathew Vithayathil, MRC Cancer Unit, University of Cambridge, Redhill, United Kingdom

FOOD ALLERGY SENSITIVITY TEST (FAST) WITH ENDOMICROSCOPY OF THE DUODENUM ENABLES TAILORED EXCLUSION DIET IN PATIENTS WITH IRRITABLE BOWEL SYNDROME
Presentation #819
Sunday, May 23 from 4:08 – 4:16 p.m. ET
Presenting Author: Ralf Kiesslich, HELIOS Dr Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Hessen, Germany

Featured poster sessions (in chronological order):

RESPONSE TO BIOLOGICS IN IBD PATIENTS ASSESSED BY COMPUTERIZED IMAGE ANALYSIS OF PROBE BASED CONFOCAL LASER ENDOMICROSCOPY WITH MOLECULAR LABELING
Poster #Fr596
Friday, May 21 from 12:15 – 1:00 p.m. ET
Presenting Author: Marietta Iacucci, Institute Translational of Medicine, Institute of Immunology and Immunotherapy and NIHR Birmingham Biomedical Research Centre, University Hospitals NHS Foundation Trust and University of Birmingham, Birmingham, UK, Birmingham, United Kingdom

PROBE BASED CONFOCAL ENDOMICROSCOPY MAY INCREASE DETECTION OF LOW GRADE DYSPLASIA IN MALE VETERANS PREVIOUSLY DIAGNOSED WITH NON DYSPLASTIC SHORT SEGMENT BARRETT’S ESOPHAGUS UNDERGOING SURVEILLANCE
Poster #Fr223
Friday, May 21 from 12:15 – 1:00 p.m. ET
Presenting Author: Karen Chang, University of California System, Oakland, California, United States

DEVELOPMENT OF CONFOCAL ENDOMICROSCOPY CRITERIA FOR EARLY SIGNET-RING CELL CARCINOMA IN PATIENTS WITH HEREDITARY DIFFUSE GASTRIC CANCER SYNDROME
Poster #Su585
Sunday, May 23 from 12:15 – 1:00 p.m. ET
Presenting Author: Nastazja Dagny Pilonis, Department of Gastroenterological Oncology, Maria-Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, Warsaw, Poland; MRC Cancer Unit, Cambridge, United Kingdom

Visitors are invited to visit our DDW 2021 virtual page: https://www.landing.maunakeatech.com/en/ddw-2021

About Digestive Disease Week® (DDW)
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is a fully virtual meeting from May 21-23, 2021. The meeting showcases more than 2,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real-time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is revolutionizing the way physicians diagnose and treat patients — making a transformative change in medicine. For more information, visit www.maunakeatech.com.

United States
Mike Piccinino, CFA
Westwicke, an ICR Company
443-213-0500

France and Europe
NewCap - Investor Relations
Thomas Grojean
+33 (0)1 44 71 94 94
maunakea@newcap.eu

Disclaimer
This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward-looking statements are subject to numerous risks and uncertainties including the risks set forth in the Universal Registration Document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on August 7, 2020 under number 926346434_20200807 and available on the Company's website (www.maunakeatech.com), and to the development of economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any country.